

Letifend (--)- Lyophilisate and solvent for solution for injection

Authorised

- Leishmania infantum, zymodeme MON-1, recombinant protein Q

Product identification

Medicine name:

Letifend (--)- Lyophilisate and solvent for solution for injection

Active substance:

Leishmania infantum, zymodeme MON-1, recombinant protein Q

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Leishmania infantum, zymodeme MON-1, recombinant protein Q

Presentation_strength: ≥36.7 ELISA Units Reference: In house Index: 0

Pharmaceutical form:

Lyophilisate and solvent for solution for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07A001

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:

Austria , Cyprus , France , Germany , Greece , Italy , Malta , Portugal , Spain

Package description:

Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 20 vials; solvent: 20 vials, Content:Lyophilisate: 1 dose; solvent: 0.8 ml

Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 10 vials; solvent: 10 vials, Content:Lyophilisate: 1 dose; solvent: 0.8 ml

Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 1 vial; solvent: 1 vial, Content:Lyophilisate: 1 dose; solvent: 0.8 ml

Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 50 vials; solvent: 50 vials, Content:Lyophilisate: 1 dose; solvent: 0.8 ml

Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 100 vials; solvent: 100 vials, Content:Lyophilisate: 1 dose; solvent: 0.8 ml

Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 5 vials; solvent: 5 vials, Content:Lyophilisate: 1 dose; solvent: 0.8 ml

Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 4 vials; solvent: 4 vials, Content:Lyophilisate: 1 dose; solvent: 0.8 ml

Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 25 vials; solvent: 25 vials, Content:Lyophilisate: 1 dose; solvent: 0.8 ml

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

LETI Pharma, S.L.U.

Marketing authorisation date:

20/04/2016

Manufacturing sites for batch release:

LETI Pharma, S.L.U.

Responsible authority:

European Commission

Authorisation number:

This information is not available for this product.

Date of authorisation status change:

20/04/2016

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 6/11/2024

Download

ema-puar-letifend-v-3865-par-en.pdf